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Abstract
Background: The progression of mild cognitive impairment (MCI) to Alzheimer’s disease (AD) dementia can be
predicted by cognitive, neuroimaging, and cerebrospinal fluid (CSF) markers. Since most biomarkers reveal
complementary information, a combination of biomarkers may increase the predictive power. We investigated
which combination of the Mini-Mental State Examination (MMSE), Clinical Dementia Rating (CDR)-sum-of-boxes, the
word list delayed free recall from the Consortium to Establish a Registry of Dementia (CERAD) test battery,
hippocampal volume (HCV), amyloid-beta1–42 (Aβ42), amyloid-beta1–40 (Aβ40) levels, the ratio of Aβ42/Aβ40,
phosphorylated tau, and total tau (t-Tau) levels in the CSF best predicted a short-term conversion from MCI to AD
dementia.
Methods: We used 115 complete datasets from MCI patients of the “Dementia Competence Network”, a German
multicenter cohort study with annual follow-up up to 3 years. MCI was broadly defined to include amnestic and
nonamnestic syndromes. Variables known to predict progression in MCI patients were selected a priori. Nine
individual predictors were compared by receiver operating characteristic (ROC) curve analysis. ROC curves of the
five best two-, three-, and four-parameter combinations were analyzed for significant superiority by a bootstrapping
wrapper around a support vector machine with linear kernel. The incremental value of combinations was tested for
statistical significance by comparing the specificities of the different classifiers at a given sensitivity of 85%.
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Results: Out of 115 subjects, 28 (24.3%) with MCI progressed to AD dementia within a mean follow-up period of
25.5 months. At baseline, MCI-AD patients were no different from stable MCI in age and gender distribution, but
had lower educational attainment. All single biomarkers were significantly different between the two groups at
baseline. ROC curves of the individual predictors gave areas under the curve (AUC) between 0.66 and 0.77, and all
single predictors were statistically superior to Aβ40. The AUC of the two-parameter combinations ranged from 0.77
to 0.81. The three-parameter combinations ranged from AUC 0.80–0.83, and the four-parameter combination from
AUC 0.81–0.82. None of the predictor combinations was significantly superior to the two best single predictors
(HCV and t-Tau). When maximizing the AUC differences by fixing sensitivity at 85%, the two- to four-parameter
combinations were superior to HCV alone.
Conclusion: A combination of two biomarkers of neurodegeneration (e.g., HCV and t-Tau) is not superior over the
single parameters in identifying patients with MCI who are most likely to progress to AD dementia, although there
is a gradual increase in the statistical measures across increasing biomarker combinations. This may have
implications for clinical diagnosis and for selecting subjects for participation in clinical trials.
Keywords: Mild cognitive impairment, Biomarkers, Tau, Phospho-tau, Amyloid-beta 42, Hippocampal volume,
Prediction, Alzheimer’s dementia
Background
Slowly progressive mild cognitive impairment (MCI) with
insidious onset often results in neurodegenerative demen-
tia, e.g., dementia due to Alzheimer’s disease (AD). A
current plausible model for the development of AD sug-
gests a temporal order of pathological brain changes; amyl-
oid deposition occurs early in the disease, but may not
directly cause clinical symptoms and is believed to trigger
neuronal injury and loss [1, 2]. Neuronal and synaptic
losses are key determinants of cognitive impairment, which
are accompanied by brain atrophy on magnetic resonance
imaging (MRI) [3, 4]. Thus, the pathological cascade in AD
is regarded as a two-stage, slowly progressive process in
which amyloidosis and neuronal injury (tauopathy and neu-
rodegeneration) are largely sequential rather than simultan-
eous processes [1, 2].
The predementia phase of AD is characterized clinically
by MCI [5], and this is accompanied by biochemical
changes in the brain reflected in the cerebrospinal fluid
(CSF) [6, 7] as well as in brain morphology on MRI [8, 9].
Specifically, impairments in delayed free-recall measures
from episodic memory tasks [10–12], reduced hippocam-
pal volumes [12–15], decreased CSF levels of amyloid-
beta1–42 (Aβ42; a marker of amyloid mismetabolism), and
elevations in tau and phosphorylated tau (p-Tau) pro-
tein (markers of axonal damage and neurofibrillary tan-
gles) [6, 14, 16–19] are the best established predictive
biomarkers of AD dementia in patients with MCI [20].
When analyzing the relation between these biomarkers
and progression to AD dementia or cognitive decline in
MCI patients, most previous studies have either determined
the strength of association between biomarkers at baseline
and cognitive/functional decline at follow-up (continuous
variables), or how well biomarker levels at baseline were
able to predict a diagnosis of AD dementia at follow-up
(dichotomous variable). The differential predictive power of
different biomarkers or combinations of biomarkers was
mainly evaluated descriptively, not by statistical testing.
A wealth of data exists to show that the brain changes
on MRI are related to CSF biomarkers, but also reveal
complementary information [11, 21, 22]. When combin-
ing two or more biomarkers simultaneously for predic-
tion of AD dementia from MCI, i.e., using MRI and CSF
[23, 24], MRI and cognitive testing [25, 26], fluorodeoxy-
glucose positron emission tomography (FDG-PET) and
CSF [27], FDG-PET and cognitive testing [28], and MRI,
CSF, and FDG-PET [29, 30], the utility of multiple bio-
marker combinations for prediction of AD dementia
from MCI was confirmed. In particular, a recent study
with an advanced multimodal classification method
revealed that 91.5% of MCI short-term progressors and
73.4% MCI nonprogressors were correctly classified
using baseline MRI, FDG-PET, and CSF data [30]. Com-
bining cognitive measures with CSF or volumetric MRI
may substantially improve risk prediction. However, in-
creasing the number of biomarker combinations did not
lead to an incremental increase in predictive power. A
combination of impaired learning ability with medial
temporal atrophy was associated with the greatest risk of
developing AD dementia from MCI [31].
A prediction of AD dementia in a foreseeable time
period, i.e., within 1 or 2 years, appears much more rele-
vant in a clinical perspective than a prediction of dementia
in the more distant future, e.g., in 10–20 years. Individuals
classified to be at “short-term risk” can receive more active
treatment and counselling. Furthermore, the proportion
of MCI patients progressing to AD dementia is not con-
stant over time, but is highest during the first years of
follow-up and decreases at longer follow-up intervals [32].
Finally, information about long-term risk of AD dementia
Frölich et al. Alzheimer's Research & Therapy  (2017) 9:84 Page 2 of 15
may be of limited practical value for patients at the end of
their lifespan. In subjects with MCI, the effects of cerebral
amyloidosis and hippocampal atrophy on the progression
to AD dementia differ, e.g., the risk profile is linear with
hippocampal atrophy but reaches a ceiling with higher
values for cerebral amyloidosis [1]. In subsequent investi-
gations, biomarkers of neuronal injury appeared to best
predict AD dementia from MCI subjects at shorter time
intervals (1–2 years) in particular [14, 18].
In the present study, we investigated which combin-
ation of cognitive markers and biomarkers can best pre-
dict progression to AD dementia in order to generate a
clinical model to predict the short-term progression to
AD dementia applicable to a help-seeking sample of
MCI patients. Knowledge on the added value of combin-
ing different biomarker modalities for the most efficient
prediction of progression to AD dementia in MCI subjects
is still limited. In our analysis, we describe the incremental
predictive power of an increasing number of combined
biomarkers to determine progression to AD dementia
from MCI subjects and test the best two- to four-
predictor combinations for superiority over each other.
Methods
Dementia Competence Network study
The diagnostic and prognostic study of the Dementia
Competence Network (DCN) is a prospective multisite
longitudinal observational study on memory clinic pa-
tients with MCI or early dementia [33]. Thirteen expert
memory clinics of German academic hospitals were in-
volved in data collection. Personnel were trained and
experienced in clinical research. Further details are avail-
able at the DCN website [34]. The DCN study was ap-
proved by the Ethics Review Board of the Erlangen
medical faculty (coordinating center) and by the Ethics
Committees at each individual center, and was con-
ducted in accordance with the Declaration of Helsinki.
All patients gave written informed consent to partici-
pate. We adhered to the Standards for Reporting Diag-
nostic accuracy (STARD) statement [35] to optimize
generalizability of the prediction model.
Subjects
Subjects were recruited between May 2003 and November
2007. They were referred to the participating specialist
memory clinics for the workup of memory complaints
and/or other cognitive deficits. In most centers, a con-
secutive series of patients was included. Detailed inclusion
and exclusion criteria were published earlier [33]. For the
present analysis, all patients had MCI at baseline.
A diagnosis of MCI was made on the basis of clinical
and neuropsychological data, without reference to CSF or
MRI volumetry results (see below). The DCN study delib-
erately used a broad definition of MCI [5]—complaints of
a cognitive deficit and objectified decline of cognitive abil-
ities (more than 1 SD below age- and education-adjusted
norms) in at least one of the following domains as evi-
denced by standardized neuropsychological tests (Consor-
tium to Establish a Registry of Dementia (CERAD)
neuropsychological test battery): verbal learning and
memory, nonverbal learning and memory, word fluency,
naming, visuoconstruction, cognitive speed, or executive
function [36]; no or only minor changes in complex
activities of daily living (ADL), as demonstrated by a
Bayer activities of daily living (B-ADL) score < 4 [37];
no major depressive episode at baseline as demon-
strated by a Montgomery-Asberg Depression Rating
Scale score < 13 [38].
With this diagnostic procedure, 1071 MCI patients
were included at baseline from which we selected a sub-
sample of 115 (12%) patients according to the following
inclusion/exclusion criteria: availability of 1) complete
baseline neuropsychological data; (2) adequately proc-
essed and quality checked MR imaging; and (3) CSF data
at baseline; (4) all had been followed for at least
12 months (mean follow-up 25.46 months) and were
clinically evaluated every 12 months up to 36 months or
until progression to incident dementia; and 5) outco-
me—MCI stable or progression to AD only. The major
focus of our research was on early prediction of AD
from normal. Since our diagnoses are based on clinical
classification at follow-up and are not pathological diag-
noses, an inclusion of subjects with progression to other
dementia diagnoses may lead to misclassification. This
potential misclassification would decrease the predictive
power of the biomarkers to be analyzed. Stable MCI pa-
tients were defined as those with no dementia (Clinical
Dementia Rating (CDR) < 1), a Mini-Mental State Exam-
ination (MMSE) score of 24 or higher at last follow-up
visit, and a B-ADL score < 4 at each follow-up.
Dementia was defined as a clinical diagnosis with
cognitive impairment in two or more cognitive domains
severe enough to interfere with normal functioning in
the community. From a detailed medical history, clinical,
neurological, and psychiatric investigation, other reasons
for an impaired cognitive performance and performance
in ADL were excluded. At follow-up, progression to
dementia was defined as newly occurring impairments
in instrumental or basic activities of daily living (B-
ADL score > 4) in subjects previously defined as having
MCI. Patients who developed a non-AD dementia at
follow-up were excluded from the analyses.
Neuropsychological procedures
All subjects were investigated with standardized diagnos-
tic procedures. Neuropsychological analysis was per-
formed as described previously [33]. The following raw
memory scores were part of the test battery series at
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baseline: the CERAD neuropsychological test battery in-
cludes a word list learning subtest. A 10-word list is read
and immediately recalled three times. After a distraction
period of 15 min, while other neuropsychological tests were
done, subjects have to recall the items presented and then
to recognize them among distractors. We here focused on
the delayed free-recall (CERAD-DR) measure. As a com-
posite measure of overall dementia severity, the CDR sum-
of-boxes (CDR-sb) was applied [39]. For comparison to
other cohorts, the MMSE was applied [40].
Collecting, storage, and shipment of the samples
Before starting collection of human body fluid samples,
standard operating procedures (SOPs) were implemented
[41]. Briefly, CSF was collected by lumbar puncture from
the L3/L4 or L4/L5 intervertebral region. No serious
adverse events were reported. CSF was sampled in
polypropylene test tubes with intermediate storage at site
(–80 °C), and was then shipped on dry ice to the central
biobank (Erlangen University) without undergoing any
thawing/refreezing cycles.
Analyses of CSF biomarkers
The following CSF biomarkers were measured by
enzyme-linked immunosorbent assay (ELISA): amyloid-
beta1-40 (Aβ40; The Genetics Co., Zürich, Switzerland),
Aβ42, total tau (t-Tau), and phosphorylated tau181 (p-Tau;
Innogenetics, Ghent, Belgium). The analyses were per-
formed by experienced laboratory technicians in a certi-
fied laboratory and under a routine quality control regime
(intra-assay coefficients of variation: 2.3–5.9%; interassay
coefficients of variation: 9.8–13.7%). The technicians were
blinded to the clinical diagnoses and other clinical infor-
mation. In addition to Aβ42, several other Aβ isoforms
are excreted into the CSF, the most abundant being Aβ40
[42]. CSF Aβ40 is relatively unchanged in AD, but the CSF
Aβ42/Aβ40 ratio (Aβ ratio) has been suggested to have
stronger diagnostic accuracy for AD compared to CSF
Aβ42 alone [43]. The ratio may normalize individuals ac-
cording to their Aβ production level, so that pathologically
low CSF Aβ42 can be identified in “high Aβ producers”
and vice versa [44]. Since it has been shown that the Aβ
ratio is useful in a clinical setting [45], we also evaluated
the predictive value of this ratio.
Hippocampal volume
MRI scans were obtained on 1.5-Tesla scanners. Special
measures were taken for standardization of MRI acquisition
across centers. Acquisition parameters were provided to all
centers as a guideline. The phantom test of the American
College of Radiology MRI Accreditation Program was con-
ducted repeatedly at 11 sites of the DCN [46]. Furthermore,
a single volunteer was investigated at each of these centers.
Hippocampal volume (HCV) was calculated as the mean
value of the left and right hemisphere, and was determined
from high-resolution structural magnetic resonance images
using the Oxford Centre for Functional MRI of the Brain
(FMRIB) Integrated Registration and Segmentation Tool
[47] from the FMRIB Software Library (FSL) package of
tools [48], since a biological relevance for using the hippo-
campal volumes of the left and right hemispheres separately
cannot be assumed.
Estimated total intracranial volume was calculated
through registration of each MRI scan to a standard
brain image template [49] using FSL FLIRT [50]. Exten-
sive quality control analysis was performed on segmen-
tations of all volumetric measures. Outliers were visually
evaluated by overlaying the automated segmentations on
the original MRI scan. Subjects were excluded from the
analysis if structures were poorly segmented.
Outcome measure and predictors
Clinical protocols were uniform across centers and strict
SOPs were implemented before recruitment of patients.
The “reference standard” was a clinical diagnosis of
probable AD dementia in a patient with previous MCI [5].
AD dementia was diagnosed according to the NINCDS-
ADRDA criteria [51]. All clinicians who collected follow-
up data or who made the diagnoses were blinded to the
results of CSF analysis and hippocampal volumetry.
The following measures were evaluated as predictors for
progression to AD dementia: MMSE, CDR-sb, CERAD-
DR, HCV, Aβ42, Aβ ratio, t-Tau, and p-Tau.
Following the recommendations in the STARD criteria
for studies of diagnostic accuracy [35], the cut-off values
for defining abnormal biomarker values (HCV and CSF
parameters) were developed in subjects that were not
part of this study. In the context of this study, percentage
abnormal values in relation to these cut-offs were used for
descriptive purposes only. Aβ42 (600 pg/ml), p-Tau (60 pg/
ml), and total tau (300 pg/ml) cut-offs were provided by the
assay producer (Innogenetics, Ghent, Belgium). For the
CERAD-DR score, a published cut-off value was used
which separated normal controls from MCI (<7) [52].
Statistical analysis
All statistical analyses were performed using the statistical
software R (version 2.3.1) [53]. A correction for multiple
testing was not performed due to the low number of tests.
Group comparisons at baseline were performed by the
Wilcoxon rank sum test for continuous and nominal vari-
ables. CSF biomarkers, hippocampal volumes, and neuro-
psychological data as well as demographic data obtained
in MCI patients at baseline were used to predict progres-
sion to AD dementia (MCI-AD) versus nonprogression
(MCI-stable). We did not control for possible center ef-
fects, MCI subtype, or length of follow-up. The predictive
power of each single parameter was evaluated by receiver
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operating characteristic (ROC) area under the curve
(AUC) analysis. Sensitivity, specificity, and Youden’s index
(sensitivity + specificity – 1) [54] of the various predictors/
prediction models were also calculated to provide a
complete description of the prediction parameters.
For comparison of the AUC values of single predictors
we used a bootstrapping algorithm as implemented in
the pROC R-package (Version 1.8) [55]. The predictive
accuracy of all possible combinations of two, three, and
four parameters was analyzed by a classification system
that consisted of a 0.632 bootstrapping wrapper (100
replications) around a support vector machine (SVM)
with linear kernel. Whether the addition of a variable
significantly increased predictive quality of models with
one, two, three, or four predictors was tested by compar-
ing the AUC distributions of 1000 bootstrapping replica-
tions for the different classifiers according to Hanley and
McNeil [56]. In each bootstrap trial, the different models
were ranked according to the AUC. For statistical testing,
we calculated a Z-score which approximately follows a
standard normal distribution.
Z
mean θ1−θ2ð Þ
sd θ1−θ2ð Þ
The p value was then calculated according to the
standard normal distribution. To demonstrate the nor-
mality of the Z values, a QQ Norm plot was calculated.
As a second way to compare the ROC curves, we evalu-
ated the ROC curves at a given sensitivity of 85%. This is
consistent with international recommendations for a
biomarker, since values above 80% are considered indica-
tive of satisfactory predictive performance [57]. Using 100
bootstrapping replications, we obtained a distribution of
specificities around a given sensitivity of 85%. To compare
the ROC curves at the given sensitivity, we used the same
procedure as described above to compare the AUCs.
Results
We analyzed 115 patients with complete datasets at
baseline and clinical follow-up. The datasets analyzed in
the current study are available from the corresponding
author on reasonable request. They were a subset from
1071 MCI subjects in whom baseline demographics and
neuropsychological test results were available. Due to
various missing data, 956 subjects could not be analyzed
(see Fig. 1 for exact patient loss). Table 1 compares the
demographic characteristics, cognitive and psychometric
test scores, hippocampal volume measures, and cerebro-
spinal fluid biomarkers at baseline between the maximal
MCI sample, in those for which the respective measures
were available, and the final analysis set (115 patients,
12% of the MCI cohort) which was used for predictor
analysis. There was no significant difference between the
groups on any parameter (with the exception of CDR-sb
which was not clinically relevant). All p values were
based on pairwise comparisons, uncorrected for multiple
testing. Table 2 summarizes the demographic character-
istics, cognitive test scores, hippocampal volume mea-
sures and cerebrospinal fluid biomarkers at baseline and
follow-up for the groups used for the prediction analysis
(final analysis set, MCI-AD, MCI-stable) and the
statistical differences between the MCI-AD and MCI-
stable groups. Of the 115 MCI patients, 28 patients
(24.3%) progressed to AD dementia (MCI-AD) after a
mean follow-up of 26.2 months corresponding to an
Fig. 1 Patient loss due to missing data. The absolute sample size is given in the rectangles; the loss of sample size due to missing data of the
respective measures is given in the diamonds. AD Alzheimer’s disease, CSF cerebrospinal fluid, MCI mild cognitive impairment
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annual conversion rate of 11.2%; 87 patients did not pro-
gress to AD (MCI-stable), and their mean follow-up was
25.2 months which was not significantly different from
the MCI-AD follow-up (Wilcoxon test, p > 0.1). In
addition, 17 MCI patients progressed to non-AD demen-
tia. Because potential misclassification between clinical
diagnosis and actual pathology may decrease the predict-
ive power of the biomarkers to be analyzed, we decided to
exclude MCI subjects with clinical progression to non-AD
dementias from our analysis. At the first follow-up (year
1), 21 out of 28 MCI subjects had progressed to AD
dementia, 5 out of the remaining 7 MCI subjects had pro-
gressed to AD dementia at the second follow-up (year 2),
and the final 2 MCI subjects had progressed to AD
dementia at the third follow-up (year 3).
Baseline characteristics
Both MCI subgroups were well matched in terms of age
and gender, and showed a similar distribution of APO E
alleles (Table 2). MCI patients progressing to AD (MCI-
AD) had fewer years of schooling, lower MMSE and
CERAD-DR scores, higher CDR-sb scores, and presented
with significantly higher t-Tau and p-Tau values, signifi-
cantly lower mean Aβ42 levels in CSF, and significantly
smaller HCV. The standardized mean difference (SMD) at
baseline was largest for the t-Tau values, followed by
HCV. Among the biomarkers analyzed, Aβ42 levels
showed the smallest SMD at baseline.
Regarding the frequency of abnormal values, 86% of
MCI-AD patients had abnormal values for t-Tau, 61%
for p-Tau, and 61% for Aβ42. The MCI-stable sub-
group had considerably lower frequencies of abnormal
biomarker values: 47% for t-Tau, 27% for p-Tau, and
25% for Aβ42.
Prediction of incipient AD
ROC curve analysis resulted in AUC of 0.71 to 0.77 for
the biomarkers t-Tau and HCV and the cognitive markers
CDR-sb, CERAD-DR, and MMSE. AUC > 0.7 corresponds
to a fair accuracy for predicting progression to AD de-
mentia. p-Tau, Aβ42, and Aβ ratio had an AUC < 0.7 and,
thus, poorly predicted progression (Table 3). Interestingly,
the sensitivities and specificities of the individual predic-
tors were inversely related to AUC values, possibly
reflecting the effect of the short-term follow-up period.
Pairwise comparisons of the single biomarker predic-
tors showed all AUC curves were significantly different
from Aβ40 (p < 0.05), but not from each other with the
one exception that t-Tau was significantly different
from p-Tau (p < 0.03) (see Table 4).
Statistical comparison of the predictive power of
biomarker combinations over individual biomarkers
To test if a combination of the best two- to four-
biomarker combinations outperforms the two best
individual biomarkers in separating progressive MCI
Table 1 Sociodemographic, clinical, and biomarker variables in the final analysis set (n = 115) and in the respective comparison
group (max. n = 956; actual group size for each variable is the maximal N available for the comparison group)
Variable Final analysis sample
(n =115) MCI-stable + MCI-AD
Comparison group (n = 956) P value
Group size (n) All other MCI with data available
Age 65.7 ± 9.0 956 67.1 ± 8.6 ns
Sex (male = 1) 1.4 ± 0.5 956 1.5 ± 0.5 ns
education 9.5 ± 1.9 956 9.5 ± 1.9 ns
MMSE 27.0 ± 2.1 956 27.2 ± 2.2 ns
MADRS 7.4 ± 5.6 908 7.8 ± 6.2 ns
B-ADL 2.5 ± 1.5 903 2.3 ± 1.4 ns
CDR-sb 1.8 ± 1.1 956 1.5 ± 1.0 0.01
CERAD-DR-WL 4.8 ± 2.3 956 5.0 ± 2.3 ns
Hippocampal volume 4450 ± 672 368 4511 ± 653 ns
Aβ42 749 ± 300 292 751 ± 353 ns
Aβ40 9654 ± 2732 268 9684 ± 3030 ns
Aβ ratio 0.08 ± 0.03 266 0.08 ± 0.04 ns
Total tau 411 ± 251 284 446 ± 304 ns
Phosphorylated tau 61 ± 30 289 67 ± 36 ns
Data are given as mean ± standard deviation
There is no significant difference between the groups with the exception of CDR-sb which is not clinically relevant
P values were uncorrected for multiple comparisons
Aβ40 amyloid-beta1–40, Aβ42 amyloid-beta1–42, AD Alzheimer’s disease, B-ADL Bayer activities of daily living, CDR-sb Clinical Dementia Rating–sum-of-boxes,
CERAD-DR-WL Consortium to Establish a Registry of Dementia–delayed recall word list, MADRS Montgomery-Asberg Depression Rating Scale, MCI cognitive
impairment, MMSE Mini-Mental State Examination, ns not significant
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(i.e., those MCI subjects who progressed to AD de-
mentia during the follow-up period (MCI-AD)) from
stable MCI, the analysis of two- to four-parameter combi-
nations of the eight predictor/biomarker indices (MMSE,
CDR-sb, CERAD-DR, HCV, Aβ42, Aβ42/Aβ40, t-Tau, and
p-Tau) were numerically superior over the performance of
a single biomarker index. Classification results for predic-
tion of progression from MCI to AD dementia (MCI-AD)
of the best one- to four-parameter predictor combinations
are given in Table 3. t-Tau was the single marker with the
highest mean bootstrap-based cross-validated AUC of 0.77,
followed by HCV (AUC = 0.74). Compatible with this,
the best two-predictor combination was t-Tau and
HCV (AUC = 0.81). The addition of a third and fourth
predictor only minimally increased the mean bootstrapping-
based cross-validated AUC (the best three-predictor com-
bination was t-Tau/HCV/CDR-sb, AUC= 0.83; the best
four-parameter combination was t-Tau/HCV/CDR-sb/Aβ
ratio, AUC= 0.82). The pairwise comparisons of AUC values
for HCV or t-Tau with the best two-, three- or four-
Table 2 Demographic characteristics, cognitive test scores, APO E allele distribution, brain volumetric measures, and cerebrospinal
fluid biomarkers at baseline and follow-up for the final analysis set (115 MCI subjects) and the two groups MCI-stable and MCI-AD
All (n = 115) MCI-stable
(n = 87)
MCI-AD
(n = 28)
Standard mean
difference*
P value**
Age (years) 65.7 ± 9.03
(36–89)
66.5 ± 8.95
(51–80)
65.4 ± 9.37
(36–89)
0.12 ns
Education (years schooling) 9.50 ± 1.91
(7–13)
9.75 ± 1.95
(7–13)
8.75 ± 1.58
(7–13)
–0.52 <0.05
Gender (female = 1, male = 2) Male = 67;
female = 48
Male = 52;
female = 35
Male = 15;
female = 13
0.13 ns
Bayer-ADL scale (score: 1–10) 2.47 ± 1.48
(1–4)
2.41 ± 1.52
(1–4)
2.67 ± 1.34
(1–4)
0.18 ns
MADRS (score: 0–60) 7.41 ± 5.75
(0–13)
7.67 ± 5.96
(0–13)
6.62 ± 5.08
(0–11)
–0.18 ns
MMSE 27.0 ± 2.12
(20–30)
27.5 ± 1.87
(22–30)
25.8 ± 2.34
(20–29)
–0.81 <0.001
CDR-sb 1.80 ± 1.06
(0.5–4.5)
1.59 ± 1.00
(0.5–4.5)
2.45 ± 0.98
(0.5–4)
0.81 <0.001
CERAD-DR-WL 4.82 ± 2.33
(0–10)
5.25 ± 2.23
(0–10)
3.46 ± 2.15
(0–8)
–0.77 0.001
Amnestic deficit: CERAD-DR-WL below cut-off
(<7 correct responses), n (% present)
88 (77%) 62 (71%) 26 (93%)
ApoE4 alleles (homo- or heterozygotes), n/sample size (% present) 41/103 (40%) 32/78 (41%) 9/25 (36%) ns
Hippocampal volume (mm3) 4450 ± 672
(2509–5996)
4585 ± 649
(3036–5996)
4031 ± 570
(2509–5235)
–0.82 <0.0001
Total tau in CSF (pg/ml) 411 ± 252
(112–1169)
351 ± 205
(112–1158)
596 ± 294
(156–1169)
0.97 <0.0001
Total tau in CSF below cut-off (>300 pg/ml), n (% abnormal) 65 (57%) 41 (47%) 24 (86%)
Phosphorylated tau in CSF (pg/ml) 61.3 ± 30.5
(19.7–157)
55.6 ± 26.3
(19.7–130)
78.8 ± 36.1
(27.3–157)
0.76 <0.01
Phosphorylated tau in CSF below cut-off (>60 pg/ml), n (% abnormal) 44 (38%) 27 (31%) 17 (61%)
Aβ42 in CSF (pg/ml) 749 ± 300
(245–1792)
794 ± 309
(276–1792)
611 ± 223
(245–1134)
–0.61 <0.001
Aβ42 in CSF below cut-off (<600 pg/ml), n (% abnormal) 39 (34%) 22 (25%) 17 (61%)
Aβ40 in CSF (pg/ml) 9654 ± 2731
(2604–16320)
9601 ± 2561
(4175–16320)
9817 ± 3251
(2604–15210)
0.08 ns
Aβ40 in CSF below cut-off, n (% abnormal) n/a n/a n/a
Follow-up time (months) 25.5 ± 9.8
(12–36)
26.1 ± 8.0
(12–36)
25.2 ± 8.9
(12–36)
ns
Values are given as means ± SD (range) unless otherwise stated
*Standardized (mean values in MCI-AD patients – mean values in MCI-stable patients)/standard deviation in the group of all patients
**P values refer to differences between MCI-stable and MCI-AD
Aβ40 amyloid-beta1–40, Aβ42 amyloid-beta1–42, AD Alzheimer’s disease, B-ADL Bayer activities of daily living, CDR-sb Clinical Dementia Rating–sum-of-boxes,
CERAD-DR-WL Consortium to Establish a Registry of Dementia–delayed recall word list, CSF cerebrospinal fluid, MADRS Montgomery-Asberg Depression Rating
Scale, MCI cognitive impairment, MMSE Mini-Mental State Examination, n/a not available, ns not significant
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predictor combinations were not significantly different. The
AUC-curves for the best one to four predictor(s) combina-
tions are illustrated in Fig. 2. When MCI subjects with pro-
gression to non-AD dementia were included in our analysis
(e.g., added to the MCI-stable group), the results remained
largely unchanged for the two- and three-parameter
combinations, but varied in the four-parameter combi-
nations (data not shown).
Finally, we compared the normalized distribution of
bootstrapped specificities at a fixed sensitivity of 85% for
the individual biomarkers HCV and t-Tau and the best
two- to four-parameter combinations. Here, the statistical
comparison of specificities at the fixed sensitivity of 85%
revealed that all two- to four-parameter combinations
were significantly superior to HCV, but only the three/
four-parameter combinations were superior to t-Tau alone
(p < 0.03, uncorrected for multiple comparisons). When
comparing the best two- to four-parameter combinations
among each other, there were no significant differ-
ences (HCV/t-Tau, HCV/t-Tau/CDR-sb, HCV/t-Tau/
CDR-sb/Aβ ratio) (p > 0.10, uncorrected for multiple
comparisons). QQ plots of standardized specificities
at the given sensitivity of 86% confirmed their standard
normal distribution (see Table 5 and Fig. 3).
Table 3 The 10 single predictors and the five best two- to four-predictor classification results predicting progression from MCI to
AD dementia
Predictors AUC Youden index Sensitivity Specificity PPV NPV
Single predictors
t-Tau 0.77 1.48 0.62 0.86 0.42 0.93
HCV 0.74 1.45 0.63 0.82 0.42 0.92
CDR-sb 0.73 1.38 0.45 0.93 0.35 0.95
CERAD-DR 0.72 1.39 0.64 0.75 0.40 0.89
MMSE 0.71 1.36 0.68 0.68 0.40 0.87
p-Tau 0.69 1.41 0.81 0.61 0.50 0.86
Aβ42 0.68 1.38 0.74 0.64 0.44 0.87
Aβ42/Aβ40 0.66 1.34 0.59 0.75 0.37 0.88
Aβ40 0.55 1.15 0.76 0.39 0.34 0.80
APO E 0.50 1.05 0.41 0.64 0.26 0.47
Two-predictor combinations
t-Tau HCV 0.81 1.45 0.68 0.77 0.49 0.88
t-Tau CDR-sb 0.79 1.44 0.83 0.61 0.41 0.92
t-Tau MMSE 0.79 1.46 0.81 0.65 0.43 0.91
t-Tau CERAD-DR 0.78 1.43 0.62 0.81 0.52 0.87
p-Tau HCV 0.77 1.40 0.76 0.64 0.42 0.89
Three-predictor combinations
t-Tau HCV CDR-sb 0.83 1.54 0.84 0.70 0.48 0.93
t-Tau HCV MMSE 0.81 1.47 0.83 0.64 0.44 0.92
t-Tau MMSE CDR-sb 0.81 1.47 0.76 0.70 0.46 0.90
t-Tau CDR-sb CERAD-DR 0.80 1.48 0.79 0.70 0.47 0.91
HCV MMSE Aβ42/Aβ40 0.80 1.48 0.78 0.70 0.45 0.91
Four-predictor combinations
t-Tau HCV CDR-sb Aβ42/Aβ40 0.82 1.55 0.89 0.67 0.47 0.95
t-Tau p-Tau CDR-sb Aβ42/Aβ40 0.82 1.49 0.78 0.71 0.47 0.91
t-Tau HCV p-Tau Aβ42/Aβ40 0.82 1.49 0.85 0.64 0.42 0.93
t-Tau HCV CDR-sb CERAD-DR 0.81 1.57 0.80 0.76 0.52 0.92
HCV MMSE CDR-sb Aβ42/Aβ40 0.81 1.51 0.86 0.65 0.46 0.93
The predictors are sorted according to the AUC
All values correspond to mean bootstrap-based cross-validated performance
Aβ40 amyloid-beta1–40, Aβ42 amyloid-beta1–42, AD Alzheimer’s disease, AUC area under the curve, CDR-sb Clinical Dementia Rating–sum-of-boxes, CERAD-DR
Consortium to Establish a Registry of Dementia–delayed recall, HCV hippocampal volume, MCI cognitive impairment, MMSE Mini-Mental State Examination, NPV
negative predictive value, PPV positive predictive value, p-Tau phosphorylated tau, t-Tau total tau
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Discussion
The power of hippocampal volume, CSF Alzheimer bio-
markers, and neuropsychological measures for predict-
ing progression from MCI to AD dementia was analyzed
in a relatively large multicentre memory clinic cohort
from the German Dementia Competence Network
(DCN). A combination of two biomarkers of neurode-
generation (e.g., HCV and t-Tau) did not predict AD de-
mentia in MCI significantly better than any parameter
alone, and none of the possible three- to four-parameter
combinations improved the predictive power. Our study
is unique in applying advanced statistical methods for
testing different biomarker combinations for superiority
over each other.
A systematic incremental combination of the nine in-
dependent predictor variables in models with maximally
four predictors allowed for the direct comparison of sin-
gle predictor models with more complex models, based
upon a bootstrapping algorithm for the AUC. There was
a numerical gain by up to 6% in AUC from the best
single-predictor model to the best four-predictor model,
but none of the differences between one-predictor models
and the best two-predictor model were statistically signifi-
cant. Only when specificities were compared for a given
sensitivity of 85% was there an inferiority of hippocampal
volume to the best two- to four-parameter combinations.
Although it is possible that a test of these models in a
larger sample or a combination of even more predictors
may lead to a generally superior multipredictor model, the
current results support the assumption that an easy to use
Table 4 P values showing pairwise statistical comparisons of single predictor receiver operating characteristic curves based on area
under the curve
HCV Aβ42 Aβ40 p-Tau t-Tau MMSE CDR-sb CERAD-DR Aβ42/Aβ40
HCV ns 0.03 ns ns ns ns ns ns
Aβ42 ns ns ns ns ns ns ns
Aβ40 0.02 0.00 0.04 0.02 0.05 0.06
p-Tau 0.03 ns ns ns ns
t-Tau ns ns ns 0.02
MMSE ns ns ns
CDR-sb ns ns
CERAD-DR ns
Significant values are shown in bold typeface
Data were not corrected for multiple testing
For comparing areas under the curve we used a bootstrapping algorithm as implemented in pROC packages (Version 1.8)
Aβ40 amyloid-beta1–40, Aβ42 amyloid-beta1–42, CDR-sb Clinical Dementia Rating–sum-of-boxes, CERAD-DR Consortium to Establish a Registry of Dementia–delayed
recall, HCV hippocampal volume, MMSE Mini-Mental State Examination, ns not significant, p-Tau phosphorylated tau, t-Tau total tau
Table 5 P values showing statistical comparisons of the
specificities of the receiver operating characteristic curves for
the best one-, two-, three-, and four-predictor combinations at a
given sensitivity of 85%
t-Tau t-Tau, HCV t-Tau, HCV,
CDR-sb
t-Tau, HCV, CDR-sb,
Aβ42/Aβ40
HCV ns 0.03 0.001 0.000
t-Tau ns 0.01 0.003
t-Tau, HCV ns ns
t-Tau, HCV, CDR-sb ns
Data were not corrected for multiple testing
For comparing the values we used a bootstrapping algorithm as implemented
in pROC packages (Version 1.8)
All predictor combinations were statistically superior to single predictors, but
none of the best three- and four-parameter combination was statistically
superior to the two-predictor combination
Aβ40 amyloid-beta1–40, Aβ42 amyloid-beta1–42, CDR-sb Clinical Dementia
Rating–sum-of-boxes, HCV hippocampal volume, ns not significant, t-Tau
total tau
Fig. 2 ROC curves of the best single and two- to four-parameter
classifiers, based on 100 replicates of a 0.632 bootstrapping algorithm
based on support vector machine classifier. A boxplot of areas under
the curves (AUCs) for the different classification engines is shown in the
insert. The AUC values of the different classification engines were not
significantly different from each other. CDR.SB Clinical Dementia
Rating–sum-of-boxes, HIPPO hippocampal volume, ttau total tau,
ratio42_40 amyloid-beta1–42/amyloid-beta1–42 ratio
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and economic one-predictor model of neurodegeneration
markers may be as good as more complex models for the
prediction of progression from MCI to AD dementia
within a relatively short time interval of 2 years. Indeed,
due to typically high collinearity of predictor variables,
more complex models are not likely to increase prediction
accuracy [58].
Our cohort of MCI patients is generated from a large
multicenter study of German university memory clinics
in patients with various degrees of cognitive impairment
ranging from subjective cognitive decline to various
forms of dementia which differs, for example, from the
Alzheimer’s Disease Neuroimaging Initiative (ADNI)
cohort in terms of setting and recruitment [33]. A selec-
tion bias of the final analysis set of moderate sample size
from the much larger total MCI cohort could not be
demonstrated in our data. MCI participants in ADNI
were carefully selected to include individuals with docu-
mented memory impairment and to exclude those
whose impairment could arise from other potential
causes. Thus, the ADNI MCI population is not represen-
tative of a general clinical population, but more of a
research population. In our sample, the inclusion and
exclusion criteria were more liberal [33] as the patients
were recruited from a help-seeking clinical sample. Also,
the neuropsychological criteria to diagnose MCI used a
more liberal threshold to define cognitive impairment,
following the criteria proposed by Winblad et al. [5].
The mean age of our sample (66 years) was considerably
younger than in ADNI (74 years) [59], and in the
DESCRIPA study (71 years) [60]. This may impact on
the proportion of subjects progressing to AD dementia
at the given follow-up rate. Clinically, 24.3% of the MCI
patients of the DCN cohort progressed to AD dementia
after a mean follow-up period of 25.5 months, corre-
sponding to an annualized conversion rate of 12%. This
rate is lower than an approximate 30% progression rate
in other multicenter cohorts with comparable follow-up
(32% DESCRIPA [60, 61], 30–44% ADNI [24, 31, 59],
and 30% AIBL [62]). After a mean follow-up period of
3.3 years, 44.6% of MCI subjects from ADNI had pro-
gressed to AD dementia [59], in line with the notion that
the likelihood of progression to AD dementia increases
with follow-up time. In summary, the lower progression
rate may be attributed to the lower mean age, a broader
definition of MCI, and differences in recruitment strat-
egy of patients in our sample compared to other cohorts
with similar follow-up time [62–64].
As in other studies, the groups of MCI-stable and
MCI-AD were not different with respect to age, educa-
tion, gender, APO E genotype, and Aβ40, and all base-
line Alzheimer biomarker levels were pathologically
changed in MCI-AD compared to MCI-stable. With
respect to their predictive power, a shorter follow-up
time generally favors biomarkers of neurodegeneration,
e.g., tau and HCV, since neurodegeneration occurs
shortly before (or even triggers) progression from MCI
to dementia stage. In univariate analyses, the biomarkers
t-Tau and HCV and the cognitive markers CDR-sb,
CERAD-DR, and MMSE fairly well predicted progres-
sion to AD dementia, while p-TAU, Aβ42, and Aβ40
only poorly predicted progression. APO E genotype did
not have any predictive value. None of the single predic-
tors reached the criterion of an AUC > 0.8 for a diagnos-
tic biomarker, suggested by a Consensus report [57].
Almost all of the two- to four-predictor combinations
increased the predictive power over the threshold AUC >
0.8, but none of the three- and four-predictor combina-
tions were significantly superior to the two-predictor com-
bination of the injury markers HCV and t-Tau. Similar to
our data, data from ADNI showed that a combination of a
measure of volumetric change and t-Tau in CSF was asso-
ciated with higher risk of progression to AD dementia
from MCI compared with each marker alone [24]. In the
European multicentre DESCRIPA study, these injury
markers predicted time to dementia in subjects with MCI
and proven amyloid pathology [65].
Diagnostic biomarkers for the cross-sectional diagnosis
of AD dementia compared to controls should have a
sensitivity and specificity above 80% [57]. Our best two-
and three-predictor combinations were both above this
Fig. 3 Boxplot of specificities at a given sensitivity of 85% for the
different predictor combinations. AUC were calculated by 100
replications of a .632 bootstrapping algorithm. p-values for
comparing specificities at the given sensitivity demonstrated the
single value predictors HCV and total tau were significantly inferior
compared to the two-four predictor combinations. None of the
predictor combinations were significantly different from each
other. CDR.SB Clinical Dementia Rating–sum-of-boxes, HIPPO
hippocampal volume, ttau total tau, ratio42_40 amyloid-beta1–42/
amyloid-beta1–42 ratio
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criterion for sensitivity but not for specificity and had a
Youden’s index > 1.45. This relative lack of specificity
may mainly be due to two reasons: 1) despite extensive
inclusion and exclusion criteria, there will be some
heterogeneity of underlying disease in MCI patients; 2)
at a mean follow-up interval of approximately 2 years
(maximum 3 years), some patients classified as MCI-
stable will not yet have progressed to AD dementia. This
hypothesis is consistent with findings of a meta-analysis
showing a trend towards increasingly higher effect sizes
of CSF biomarkers including t-Tau, p-Tau and Aβ42
during longer clinical follow-up [66]. In conclusion, the
distinction of clinical entities (healthy versus diseased)
differs between a short-term prediction of progression to
AD dementia as compared to a cross-sectional diagnosis
of AD dementia.
Three aspects of the data on individual predictors
deserve comment. Firstly our data are based on a vari-
able length of follow-up (1–3 years) which optimizes the
available study information. A homogeneous follow-up
of, for example, 1 year resulted in lower predictive values
due to a reduced number of subjects progressing to AD
dementia (21 instead of 28 patients). Hippocampal
volume and total tau remained the best single predictors
and two-parameter combinations. Furthermore, the order
of the best three-predictor combination also remained
unchanged (data not shown). Thus, any restriction to a
homogenous short follow-up time will underestimate the
predictive power of all parameters. Scientifically, a follow-
up time until death of study participants would be desir-
able, but this would be accompanied by considerable
drop-out due to various age- and disease-associated rea-
sons. From a clinical standpoint, a follow-up time of 2–3
years may be an acceptable compromise to inform pa-
tients with MCI about their foreseeable future, rather than
a follow-up time of, for example, 10 years or more,
because their life expectancy may be limited. Also, the in-
clusion of 17 non-AD converters into the MCI-stable
group did not impact our analysis. This suggests that our
model could apply to unselected MCI subjects, although
the large drop-out rate due to loss to follow-up and miss-
ing biomarker information limits the generalizability.
Secondly, with respect to CSF analyses, it has been argued
that a lumbar puncture (LP) for CSF protein analysis may
be too invasive for routine use in patients with dementia
or MCI. Although there are some contraindications to LP,
several studies have shown negligible frequency of compli-
cations, especially in the elderly. This supports a routine
analysis of CSF biomarkers as part of the clinical diagnos-
tic workup of patients with cognitive impairment possibly
due to AD [67]. Thirdly, Aβ42 in CSF was abnormal in
just 34% of the total MCI sample. In the MCI-AD sub-
group, which consisted largely of patients with amnestic
MCI (26/28 patients), roughly two-thirds of the patients
had abnormal Aβ42 values. The remaining third of pa-
tients would have to be classified as suspected non-AD
pathophysiology (SNAP), at a frequency roughly consist-
ent with a previous review [68]. Again, our sample of pa-
tients is more representative of a general help-seeking
memory clinic population, and a greater heterogeneity of
underlying disease in MCI patients is to be expected as
compared to a research population. Also, Aβ42 in CSF
was the individual parameter least predictive for progres-
sion to AD dementia. In a previous publication on MCI
patients from the DCN [69], episodic memory mea-
sures were highly significantly related to a CSF AD+
signature (Hulstead score, which includes measures of
Aβ42 and t-Tau [70]). This suggests that our sample
does contain an enriched sample of patients with
incipient Alzheimer pathology.
However, at the short follow-up interval of approxi-
mately 2 years (maximum 3 years), some patients classi-
fied as MCI-stable will not yet have progressed to AD
dementia and biomarkers of neurodegeneration will be
favored over biomarkers of amyloid pathology in predict-
ing progression to AD dementia. This assumption is
supported by the poorer specificity of Aβ42 compared to
t-Tau (0.64 versus 0.86), which reflects a lower ratio of
negative cases (i.e., such MCI subjects that will remain
stable over a much longer observation period), whereas
the sensitivity (a ratio of such MCI cases that characterize
with pathological biomarkers and have already progressed
to dementia) of Aβ42 is superior to t-Tau (0.74 versus
0.62) and slightly superior to hippocampal volume (0.71).
Comparable data were obtained by Davatzikos et al. [71]
in a subset of patients for whom both CSF and spatial pat-
terns of brain atrophy AD score (SPARE-AD) values were
available. However, some further analyses of ADNI data
with longer follow-up [59] and DESCRIPA data [61] are in
disagreement with the relative superiority of CSF t-Tau
over CSF Aβ42 in predictor combinations. It had been
suggested that the ratio of Aβ42/Aβ40 may improve the
validity of the CSF amyloid AD biomarker for diagnosis
[43, 44]. In our dataset, however, the Aβ42/Aβ40 ratio was
not consistently superior to Aβ42 alone for predicting AD
dementia in MCI patients.
In several analyses using diverse subgroups of MCI pa-
tients from the ADNI cohort, several combinations of
different biomarkers were tested to predict future cogni-
tive decline or progression to AD dementia; different
measures of cortical atrophy including hippocampal
volume and, less significantly, the tau/Aβ-42 ratio, pre-
dicted cognitive decline in MCI [29]. Landau et al. [11]
found that several biomarkers predicted cognitive de-
cline in univariate models, but only reduced glucose
metabolism and episodic memory predicted progression
to AD. Ewers et al. [59] in their comparison of the
effectiveness of single variables and multiple variables in
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predicting the conversion of MCI to AD found that the
best single predictors were comparable in accuracy with
the best multiple predictor models, which included right
hippocampal volume, CSF p-Tau/Aβ42, TMT-B, and age.
Davatzikos et al. [71] reported that the best combination
of biomarkers for predicting AD dementia from MCI
was a combination of SPARE-AD score, summarizing
brain atrophy patterns, with CSF total tau. Gomar et al.
[12] found that their most predictive model included
two measures of episodic memory and one MR volume
measure. An approach using the weighted fusion of data
from both high- and low-dimensional modalities [72]
found that MCI to AD conversion was optimally pre-
dicted by a combination of FDG-PET, MRI shape infor-
mation, and CSF biomarkers, although CSF biomarkers
added only minor improvement. By integrating multi-
modal data in a probabilistic manner, Young et al. [73]
predicted conversion of MCI to AD over 3 years with an
accuracy of 72.2%. Heister et al. [31] stratified the ADNI
MCI cohort by degree of MR atrophy, CSF biomarker
levels, or the degree of learning impairment, and
assessed the contribution of each factor to the MCI to
AD conversion. Learning impairment plus MR atrophy
were associated with the highest risk (HR = 29.0) for
conversion. A lack of sensitivity of Aβ42 for prediction
was noted. Trzepacz et al. [74] analyzed 29 numeric neu-
roimaging variables for their performance for predicting
conversion from MCI to AD dementia at 2 years. MRI
measures had the highest predictive accuracy (67%)
which increased (76%) when combined with PIB-PET,
producing the highest accuracy among any biomarker
combination. For the DESCRIPA cohort, a multicenter
European cohort with a 5-year follow-up period, it has
been shown that in subjects with MCI and evidence of
amyloid pathology, the injury markers CSF t-Tau, p-Tau,
and hippocampal atrophy can best predict cognitive de-
cline [60]. Similarly, earlier studies with smaller sample
sizes have shown that a combination of hippocampal
volume on MRI and CSF-based biomarkers may increase
prediction accuracy [23, 75].
Limitations
The present study has some limitations. Firstly, only pa-
tients who were subjected to a CSF analysis at baseline and
were able to undergo MRI and who returned for clinical
follow-up were analyzed. However, a sampling bias in our
final analysis set could not be demonstrated. Secondly, the
variability of CSF biomarker levels between laboratories
[76–80] makes it difficult to introduce generally applicable
cut-off values. To minimize variability we had installed
SOPs for pre-analytical sample handling prior to the initi-
ation of the study [41] and analyzed the CSF samples in
one centre only. Thirdly, and as in most other predictive
studies, patient classification relied on a clinical diagnosis
which is not always accurate, especially at early stages of
the disease. None of the cases investigated here was neuro-
pathologically verified. This was one of the reasons for
excluding patients from our analyses who progressed to
other forms of dementia. Fourthly, our study was per-
formed in a memory clinic setting with a tertiary referral
structure and therefore should be replicated in other more
general settings. This might lead to datasets with a number
of incomplete cases. However, the advanced diagnostic
procedures (MRI and LP) will be restricted to specialist
centers and motivated patients (typical for tertiary referral
samples or a memory clinic population) if ever imple-
mented into clinical practice. This may facilitate the
generation of complete datasets as used in our study.
Furthermore, our statistical methods require complete
datasets to allow group comparisons by bootstrapping
algorithms. Finally, we applied a relatively short follow-
up period with a mean of 2 years, meaning that a cer-
tain proportion of patients who were classified as stable
are likely to progress to dementia later on. This may
explain the low positive predictive value, a value which
had not been explicitly referred to before. However, the
successful short-term prediction is also a particular
strength of the study (see above).
There are several other strengths of the study presented
here. It is a large prospective multicentre study investigat-
ing the predictive properties of core dementia biomarkers
with uniform protocols across centers and with prior in-
stallation of SOPs, including the use of appropriate CSF
sample tubes and overall standardized pre-analytical CSF
handling. The patients were phenotyped and followed-up
in expert university memory clinics, which increases the
quality of the diagnostic workup. We adhered to the
STARD recommendations. All these measures should
optimize the generalizability of the results.
Conclusion
Our results show that a combination of two biomarkers
of neurodegeneration (e.g., HCV and t-Tau) is not super-
ior over the single parameters alone in identifying pa-
tients with MCI who are most likely to progress to AD
dementia within a relatively short time period. However,
there is a gradual increase in the statistical measures
across increasing biomarker combinations (always in-
volving t-Tau and HCV as the best parameters). From
our data it is not possible to deduct recommendations
on how to optimize the predictive diagnosis in individual
patients with MCI in clinical practice. For enrichment
strategies of MCI patients progressing to AD dementia
for clinical trials, a combination of two neurodegenera-
tion parameters (HCV and t-Tau) in addition to clinical
measures such as CDR-sb may maximize progression
rates in order to minimize false negative results of
intervention studies.
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